臨床眼科71巻7号

2017年07月発行

連載 今月の話題

網膜静脈閉塞症に対する抗VEGF治療の最新知識

著者： 西信良嗣¹

所属機関： ¹滋賀医科大学眼科学講座

ページ範囲：P.977 - P.984

　従来のRVOの治療は，格子状光凝固やトリアムシノロン硝子体内注射が中心であった。2013年にラニビズマブが適応承認を取得し，現在では抗VEGF薬硝子体内注射が標準治療である。本稿では，抗VEGF薬硝子体内注射の大規模臨床試験の最新の知見を紹介するとともにRVOの黄斑浮腫に対する新しい候補薬に関しても述べる。

参考文献

1）Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 98：271-282, 1984

2）Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 102：1425-1433, 1995

3）Ip MS, Scott IU, VanVeldhuisen PC et al：A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion：the Standard Care vs Corticosteroid for Retinal Vein Occlusion（SCORE）study report 5. Arch Ophthalmol 127：1101-1114, 2009

4）Campochiaro PA, Heier JS, Feiner L et al：Ranibizumab for macular edema following branch retinal vein occlusion：six-month primary end point results of a phase Ⅲ study. Ophthalmology 117：1102-1112, 2010

5）Brown DM, Campochiaro PA, Bhisitkul RB et al：Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion：12-month outcomes of a phase Ⅲ study. Ophthalmology 118：1594-1602, 2011

6）Brown DM, Campochiaro PA, Singh RP et al：Ranibizumab for macular edema following central retinal vein occlusion：six-month primary end point results of a phase Ⅲ study. Ophthalmology 117：1124-1133, 2010

7）Campochiaro PA, Brown DM, Awh CC et al：Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion：twelve-month outcomes of a phase Ⅲ study. Ophthalmology 118：2041-2049, 2011

8）Heier JS, Campochiaro PA, Yau L et al：Ranibizumab for macular edema due to retinal vein occlusions：long-term follow-up in the HORIZON trial. Ophthalmology 119：802-809, 2012

9）Campochiaro PA, Sophie R, Pearlman J et al：Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab：the RETAIN study. Ophthalmology 121：209-219, 2014

10）Boyer D, Heier J, Brown DM et al：Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion：six-month results of the phase 3 COPERNICUS study. Ophthalmology 119：1024-1032, 2012

11）Brown DM, Heier JS, Clark WL et al：Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion：1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155：429-437, 2013

12）Heier JS, Clark WL, Boyer DS et al：Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion：two-year results from the COPERNICUS study. Ophthalmology 121：1414-1420, 2014

13）Holz FG, Roider J, Ogura Y et al：VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion：6-month results of the phase Ⅲ GALILEO study. Br J Ophthalmol 97：278-284, 2013

14）Korobelnik JF, Holz FG, Roider J et al：Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion：one-year results of the phase 3 GALILEO study. Ophthalmology 121：202-208, 2014

15）Ogura Y, Roider J, Korobelnik JF et al：Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion：18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158：1032-1038, 2014

16）Campochiaro PA, Clark WL, Boyer DS et al：Intravitreal aflibercept for macular edema following branch retinal vein occlusion：the 24-week results of the VIBRANT study. Ophthalmology 122：538-544, 2015

17）Clark WL, Boyer DS, Heier JS et al：Intravitreal aflibercept for macular edema following branch retinal vein occlusion：52-week results of the VIBRANT study. Ophthalmology 123：330-336, 2016

18）Campochiaro PA, Hafiz G, Mir TA et al：Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion：the RELATE trial. Ophthalmology 122：1426-1437, 2015

19）Iesato Y, Imai A, Hirano T et al：Effect of leaking capillaries and microaneurysms in the perifoveal capillary network on resolution of macular edema by anti-vascular endothelial growth factor treatment. Jpn J Ophthalmol 60：86-94, 2016

20）Larsen M, Waldstein SM, Boscia F et al：Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion：twelve-month results of the CRYSTAL study. Ophthalmology 123：1101-1111, 2016

21）Tadayoni R, Waldstein SM, Boscia F et al：Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion：six-month results of BRIGHTER. Ophthalmology 123：1332-1344, 2016

22）Bremond-Gignac D：Investigational drugs for retinal vein occlusion. Expert Opin Investig Drugs 25：841-850, 2016

23）Sun Z, Zhou H, Lin B et al：Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion. Retina 2016 Nov 23［Epub ahead of print］

24）Wroblewski JJ, Hu AY：Topical squalamine 0.2％ and intravitreal ranibizumab 0.5mg as combination therapy for macular edema due to branch and central retinal vein occlusion：an open-label, randomized study. Ophthalmic Surg Lasers Imaging Retina 47：914-923, 2016